StockData

Biofrontera vs SIGA Technologies

BFRI and SIGA side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How BFRI and SIGA compare

SIGA Technologies is the larger company, worth 16 times as much as Biofrontera ($226M against $13.9M).

Biofrontera grew revenue faster over the last twelve months (17.8% versus −69.6% for SIGA Technologies).

SIGA Technologies keeps more of each dollar of sales as profit, with a net margin of 1.3% compared with −13.8% at Biofrontera.

SIGA Technologies pays a dividend yielding 19.1%; Biofrontera does not pay one.

SIGA Technologies scores higher on the StockData Score (14 against 9 for Biofrontera), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricBFRISIGA
Size and price
Market cap$13.9M$226M
Share price$0.938$3.14
Change, 1 year−9.9%−51.8%
Change, 5 years−98.2%−66.1%
Beta (5Y)1.021.10
Employees9249
StockData Score
Total score914 (better)
Valuation score03 (better)
Growth score2 (better)0
Performance score22
Health score56 (better)
Dividend score03 (better)
Valuation
P/S0.3× (better)4.3×
P/B2.3×1.4× (better)
FCF yield−57.0%–
Fair value–$6.12
Margin of safety–48.7%
Growth
Revenue growth (TTM)17.8% (better)−69.6%
Revenue growth, 5Y average17.2% (better)−5.4%
Net income growth (TTM)–−99.1%
EPS growth (TTM)–−100%
EPS growth, 5Y average–−14.7%
Profitability
Gross margin–54.0%
Operating margin−14.2%−14.2% (better)
Net margin−13.8%1.3% (better)
FCF margin−17.2%–
Return on equity−988%0.37% (better)
Return on invested capital–−15.0%
Financial health
Debt / equity0.000.00
Current ratio1.1824.57 (better)
Altman Z-score−6.1815.02 (better)
Piotroski F-score36 (better)
Dividends and buybacks
Dividend yield–19.1%
Payout ratio–6325%
Years of dividend growth–0
Shareholder yield0.00%19.1% (better)
Ownership
Held by institutions19.7%48.5%
Held by insiders23.6%1.9%
Short interest, % of float–5.1%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.